Patents by Inventor Martin John Perry

Martin John Perry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11382902
    Abstract: The present invention relates to a compound and composition for use in the stimulation of IL-12 production and IFN-? production, which compound is selected from: tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, or a pharmaceutically acceptable salt, hydrate or solvate thereof; and N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 12, 2022
    Inventors: David Festus Charles Moffat, Martin John Perry, Stephen Mark Anderton, Clare Louise Doris
  • Publication number: 20200360359
    Abstract: The present invention relates to a compound and composition for use in the stimulation of IL-12 production and IFN-? production, which compound is selected from: tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, or a pharmaceutically acceptable salt, hydrate or solvate thereof; and N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine.
    Type: Application
    Filed: August 30, 2018
    Publication date: November 19, 2020
    Applicant: Macrophage Pharma Limited
    Inventors: David Festus Charles Moffat, Martin John Perry, Stephen Mark Anderton, Clare Louise Doris
  • Patent number: 6291199
    Abstract: Recombinant human phosphodiesterase type IVC is described, and DNA coding for it. Particular conformers of the enzyme are identified, including a R- and S-rolipram stereoselective conformer which is obtainable by expression of human phosphodiesterase type IVC DNA in mammalian or insect cells. The recombinant enzyme may be used in a screen to select a compound capable of modulating the action of the enzyme, or as an immunogen to generate an antibody.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: September 18, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Raymond John Owens, Martin John Perry, Simon Mark Lumb
  • Patent number: 5861265
    Abstract: A device for performing an enzyme-labelled binding assay comprises an absorbent material and a developing solution containing a substrate for said enzyme, wherein the absorbent material is provided with a plurality of reagent zones including an indicator reagent zone and is capable of transporting the developing solution by capillary action sequentially through the reagent zones, and wherein the indicator reagent zone includes a reagent capable, directly or indirectly, of immobilizing an enzyme-labelled reagent in an amount dependent on the assay result, characterized in that the absorbent material includes a reagent that prevents a signal formation except where enzyme-labelled reagent is immobilized at the indicator reagent zone. The absorbent material is suitably in the form of an elongate strip provided with transverse reagent zones. The device is useful for performing immunoassays, including immunometric assays and dual analyte assays.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 19, 1999
    Assignee: Alusuisse Holdings AG
    Inventor: Martin John Perry
  • Patent number: 5851784
    Abstract: Recombinant human phosphodiesterase type IVC is described, and DNA coding for it. Particular conformers of the enzyme are identified, including a R- and S-rolipram stereoselective conformer which is obtainable by expression of human phosphodiesterase type IVC DNA in mammalian or insect cells. The recombinant enzyme may be used in a screen to select a compound capable of modulating the action of the enzyme, or as an immunogen to generate an antibody.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: December 22, 1998
    Assignee: Celltech Therapeutics, Limited
    Inventors: Raymond John Owens, Martin John Perry, Simon Mark Lumb
  • Patent number: 5641639
    Abstract: A device for performing an enzyme-labelled binding assay comprises an absorbent material and a developing solution containing a substrate for said enzyme, wherein the absorbent material is provided with a plurality of reagent zones including an indicator reagent zone and is capable of transporting the developing solution by capillary action sequentially through the reagent zones, and wherein the indicator reagent zone includes a reagent capable, directly or indirectly, of immobilising an enzyme-labelled reagent in an amount dependent on the assay result, characterized in that the absorbent material includes a reagent that prevents a signal formation except where enzyme-labelled reagent is immobilised at the indicator reagent zone. The absorbent material is suitably in the form of an elongate strip provided with transverse reagent zones. The device is useful for performing immunoassays, including immunometric assays and dual analyte assays.
    Type: Grant
    Filed: November 3, 1993
    Date of Patent: June 24, 1997
    Assignee: Celltech Therapeutics Limited
    Inventor: Martin John Perry